MedPath

Donga Haksuk

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

49

Active:1
Completed:33

Trial Phases

4 Phases

Phase 1:9
Phase 3:6
Phase 4:9
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials

Not Applicable
24 (50.0%)
Phase 1
9 (18.8%)
Phase 4
9 (18.8%)
Phase 3
6 (12.5%)

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Phase 4
Conditions
Renal Insufficiency, Chronic
Cardiac Catheterization
Percutaneous Coronary Intervention
Interventions
First Posted Date
2022-02-04
Last Posted Date
2022-02-04
Lead Sponsor
Dong-A University
Target Recruit Count
600
Registration Number
NCT05225077
Locations
🇰🇷

Dong A University Hospital, Busan, Korea, Republic of

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Phase 4
Conditions
Acute Myocardial Infarction
Ticagrelor
Interventions
First Posted Date
2022-01-27
Last Posted Date
2022-01-27
Lead Sponsor
Dong-A University
Target Recruit Count
120
Registration Number
NCT05210595
Locations
🇰🇷

DongA University Hospital, Busan, Korea, Republic of

Ticagrelor De-escalation Strategy in East Asian Patients With AMI

Phase 4
Conditions
Acute Myocardial Infarction
Interventions
First Posted Date
2021-02-16
Last Posted Date
2021-02-16
Lead Sponsor
Dong-A University
Target Recruit Count
2000
Registration Number
NCT04755387
Locations
🇰🇷

DongA University Hospital, Busan, Korea, Republic of

3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI

Phase 4
Conditions
ST Elevation Myocardial Infarction
Interventions
First Posted Date
2020-09-30
Last Posted Date
2020-12-22
Lead Sponsor
Dong-A University
Target Recruit Count
1002
Registration Number
NCT04570345
Locations
🇰🇷

Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of

Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

Not Applicable
Conditions
Dilated Cardiomyopathy
First Posted Date
2019-11-22
Last Posted Date
2020-08-26
Lead Sponsor
Dong-A University
Target Recruit Count
40
Registration Number
NCT04174456
Locations
🇰🇷

Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath